Alzheimer’s Disease

Establishing the UK DRI Biomarker Factory

Defining the microglia proteome and how it changes in Alzheimer’s disease

Access to Alzheimer’s disease diagnostic biomarkers in clinical routine

A future scenario: digital and blood biomarkers for Alzheimer’s disease diagnosis in primary care

How can researchers use the UK DRI Biomarker Factory?

Understanding microglia heterogeneity and plasticity in health and disease

Microglia phenotypic transitions in neurodegenerative diseases

Current and future role of tau-PET in dementia daily practice

Lecanemab: drawbacks to consider

Lecanemab: a review

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Lecanemab vs aducanumab

Primary care digital screening tool for Alzheimer’s disease

Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis

Remaining challenges in bringing fluid biomarkers into clinical practice

Bringing the pTau/Aβ42 biomarker into the clinic